Proprotein convertase subtilisin/kexin type 9 (PCSK9) is involved in cholesterol homeostasis and inflammation, platelet activation, and atherosclerosis disease progression.
This infographic presents the physiological functions and molecular features that make PCSK9 an attractive therapeutic target for cardiovascular diseases.
Various strategies for targeting PCSK9 and clinical trials involving PCSK9-inhibitors are also delineated.
Schütt K, Federici M, Verket M, et al.
Journal: Eur Heart J
First published: April 14, 2024 DOI: 10.1093/eurheartj/ehad881